Global Peptide Cancer Vaccine Sales 麻豆原创 Report 2023

Publication ID:

PB501238743

Publication Date:

January 4, 2023

Pages:

134

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,000.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
麻豆原创 Analysis and Insights: Global Peptide Cancer Vaccine 麻豆原创
Due to the COVID-19 pandemic, the global Peptide Cancer Vaccine market size is estimated to be worth US$ 546.9 million in 2022 and is forecast to a readjusted size of US$ 1964.1 million by 2029 with a CAGR of 19.8% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, ITK-1 accounting for % of the Peptide Cancer Vaccine global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Breast Cancer segment is altered to an % CAGR throughout this forecast period.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
Global Peptide Cancer Vaccine Scope and 麻豆原创 Size
The global Peptide Cancer Vaccine market is segmented by company, region (country), pipeline and application. Players, stakeholders, and other participants in the global Peptide Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), pipeline and application for the period 2018-2029.
Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Peptide Cancer Vaccine 麻豆原创 Overview
1.1 Peptide Cancer Vaccine Product Scope
1.2 Peptide Cancer Vaccine Segment by Pipeline
1.2.1 Global Peptide Cancer Vaccine Sales by Pipeline (2018 & 2022 & 2029)
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Peptide Cancer Vaccine Segment by Application
1.3.1 Global Peptide Cancer Vaccine Sales Comparison by Application (2018 & 2022 & 2029)
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Peptide Cancer Vaccine 麻豆原创 Estimates and Forecasts (2018-2029)
1.4.1 Global Peptide Cancer Vaccine 麻豆原创 Size in Value Growth Rate (2018-2029)
1.4.2 Global Peptide Cancer Vaccine 麻豆原创 Size in Volume Growth Rate (2018-2029)
1.4.3 Global Peptide Cancer Vaccine Price Trends (2018-2029)
2 Peptide Cancer Vaccine Estimates and Forecasts by Region
2.1 Global Peptide Cancer Vaccine 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2 Global Peptide Cancer Vaccine Retrospective 麻豆原创 Scenario by Region (2018-2023)
2.2.1 Global Peptide Cancer Vaccine Sales 麻豆原创 Share by Region (2018-2023)
2.2.2 Global Peptide Cancer Vaccine Revenue 麻豆原创 Share by Region (2018-2023)
2.3 Global Peptide Cancer Vaccine 麻豆原创 Estimates and Forecasts by Region (2024-2029)
2.3.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts by Region (2024-2029)
2.3.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2024-2029)
2.4 Geographic 麻豆原创 Analysis: 麻豆原创 Facts & Figures
2.4.1 United States Peptide Cancer Vaccine Estimates and Projections (2018-2029)
2.4.2 Europe Peptide Cancer Vaccine Estimates and Projections (2018-2029)
2.4.3 China Peptide Cancer Vaccine Estimates and Projections (2018-2029)
2.4.4 Japan Peptide Cancer Vaccine Estimates and Projections (2018-2029)
2.4.5 Southeast Asia Peptide Cancer Vaccine Estimates and Projections (2018-2029)
2.4.6 India Peptide Cancer Vaccine Estimates and Projections (2018-2029)
3 Global Peptide Cancer Vaccine Competition Landscape by Players
3.1 Global Top Peptide Cancer Vaccine Players by Sales (2018-2023)
3.2 Global Top Peptide Cancer Vaccine Players by Revenue (2018-2023)
3.3 Global Peptide Cancer Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2022)
3.4 Global Peptide Cancer Vaccine Average Price by Company (2018-2023)
3.5 Manufacturers Peptide Cancer Vaccine Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Peptide Cancer Vaccine 麻豆原创 Size by Pipeline
4.1 Global Peptide Cancer Vaccine Historic 麻豆原创 Review by Pipeline (2018-2023)
4.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2018-2023)
4.1.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2018-2023)
4.1.3 Global Peptide Cancer Vaccine Price by Pipeline (2018-2023)
4.2 Global Peptide Cancer Vaccine 麻豆原创 Estimates and Forecasts by Pipeline (2024-2029)
4.2.1 Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2024-2029)
4.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2024-2029)
4.2.3 Global Peptide Cancer Vaccine Price Forecast by Pipeline (2024-2029)
5 Global Peptide Cancer Vaccine 麻豆原创 Size by Application
5.1 Global Peptide Cancer Vaccine Historic 麻豆原创 Review by Application (2018-2023)
5.1.1 Global Peptide Cancer Vaccine Sales by Application (2018-2023)
5.1.2 Global Peptide Cancer Vaccine Revenue by Application (2018-2023)
5.1.3 Global Peptide Cancer Vaccine Price by Application (2018-2023)
5.2 Global Peptide Cancer Vaccine 麻豆原创 Estimates and Forecasts by Application (2024-2029)
5.2.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2024-2029)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2024-2029)
5.2.3 Global Peptide Cancer Vaccine Price Forecast by Application (2024-2029)
6 United States Peptide Cancer Vaccine 麻豆原创 Facts & Figures
6.1 United States Peptide Cancer Vaccine Sales by Company
6.1.1 United States Peptide Cancer Vaccine Sales by Company (2018-2023)
6.1.2 United States Peptide Cancer Vaccine Revenue by Company (2018-2023)
6.2 United States Peptide Cancer Vaccine Sales Breakdown by Pipeline
6.2.1 United States Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
6.2.2 United States Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
6.3 United States Peptide Cancer Vaccine Sales Breakdown by Application
6.3.1 United States Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
6.3.2 United States Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
7 Europe Peptide Cancer Vaccine 麻豆原创 Facts & Figures
7.1 Europe Peptide Cancer Vaccine Sales by Company
7.1.1 Europe Peptide Cancer Vaccine Sales by Company (2018-2023)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Company (2018-2023)
7.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline
7.2.1 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
7.2.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
7.3 Europe Peptide Cancer Vaccine Sales Breakdown by Application
7.3.1 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
7.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
8 China Peptide Cancer Vaccine 麻豆原创 Facts & Figures
8.1 China Peptide Cancer Vaccine Sales by Company
8.1.1 China Peptide Cancer Vaccine Sales by Company (2018-2023)
8.1.2 China Peptide Cancer Vaccine Revenue by Company (2018-2023)
8.2 China Peptide Cancer Vaccine Sales Breakdown by Pipeline
8.2.1 China Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
8.2.2 China Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
8.3 China Peptide Cancer Vaccine Sales Breakdown by Application
8.3.1 China Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
8.3.2 China Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
9 Japan Peptide Cancer Vaccine 麻豆原创 Facts & Figures
9.1 Japan Peptide Cancer Vaccine Sales by Company
9.1.1 Japan Peptide Cancer Vaccine Sales by Company (2018-2023)
9.1.2 Japan Peptide Cancer Vaccine Revenue by Company (2018-2023)
9.2 Japan Peptide Cancer Vaccine Sales Breakdown by Pipeline
9.2.1 Japan Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
9.2.2 Japan Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
9.3 Japan Peptide Cancer Vaccine Sales Breakdown by Application
9.3.1 Japan Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
9.3.2 Japan Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
10 Southeast Asia Peptide Cancer Vaccine 麻豆原创 Facts & Figures
10.1 Southeast Asia Peptide Cancer Vaccine Sales by Company
10.1.1 Southeast Asia Peptide Cancer Vaccine Sales by Company (2018-2023)
10.1.2 Southeast Asia Peptide Cancer Vaccine Revenue by Company (2018-2023)
10.2 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Pipeline
10.2.1 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
10.2.2 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
10.3 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Application
10.3.1 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
10.3.2 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
11 India Peptide Cancer Vaccine 麻豆原创 Facts & Figures
11.1 India Peptide Cancer Vaccine Sales by Company
11.1.1 India Peptide Cancer Vaccine Sales by Company (2018-2023)
11.1.2 India Peptide Cancer Vaccine Revenue by Company (2018-2023)
11.2 India Peptide Cancer Vaccine Sales Breakdown by Pipeline
11.2.1 India Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2023)
11.2.2 India Peptide Cancer Vaccine Sales Breakdown by Pipeline (2024-2029)
11.3 India Peptide Cancer Vaccine Sales Breakdown by Application
11.3.1 India Peptide Cancer Vaccine Sales Breakdown by Application (2018-2023)
11.3.2 India Peptide Cancer Vaccine Sales Breakdown by Application (2024-2029)
12 Company Profiles and Key Figures in Peptide Cancer Vaccine Business
12.1 Boston Biomedical
12.1.1 Boston Biomedical Corporation Information
12.1.2 Boston Biomedical Business Overview
12.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.1.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
12.1.5 Boston Biomedical Recent Development
12.2 Ultimovacs
12.2.1 Ultimovacs Corporation Information
12.2.2 Ultimovacs Business Overview
12.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.2.4 Ultimovacs Peptide Cancer Vaccine Products Offered
12.2.5 Ultimovacs Recent Development
12.3 BrightPath Biotherapeutics
12.3.1 BrightPath Biotherapeutics Corporation Information
12.3.2 BrightPath Biotherapeutics Business Overview
12.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
12.3.5 BrightPath Biotherapeutics Recent Development
12.4 TapImmune
12.4.1 TapImmune Corporation Information
12.4.2 TapImmune Business Overview
12.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.4.4 TapImmune Peptide Cancer Vaccine Products Offered
12.4.5 TapImmune Recent Development
12.5 Immatics
12.5.1 Immatics Corporation Information
12.5.2 Immatics Business Overview
12.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.5.4 Immatics Peptide Cancer Vaccine Products Offered
12.5.5 Immatics Recent Development
12.6 Sellas
12.6.1 Sellas Corporation Information
12.6.2 Sellas Business Overview
12.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.6.4 Sellas Peptide Cancer Vaccine Products Offered
12.6.5 Sellas Recent Development
12.7 Imugene
12.7.1 Imugene Corporation Information
12.7.2 Imugene Business Overview
12.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.7.4 Imugene Peptide Cancer Vaccine Products Offered
12.7.5 Imugene Recent Development
12.8 VAXON Biotech
12.8.1 VAXON Biotech Corporation Information
12.8.2 VAXON Biotech Business Overview
12.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.8.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
12.8.5 VAXON Biotech Recent Development
12.9 Generex Biotechnology
12.9.1 Generex Biotechnology Corporation Information
12.9.2 Generex Biotechnology Business Overview
12.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.9.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
12.9.5 Generex Biotechnology Recent Development
12.10 ISA Pharmaceuticals
12.10.1 ISA Pharmaceuticals Corporation Information
12.10.2 ISA Pharmaceuticals Business Overview
12.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
12.10.5 ISA Pharmaceuticals Recent Development
12.11 OncoTherapy Science
12.11.1 OncoTherapy Science Corporation Information
12.11.2 OncoTherapy Science Business Overview
12.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
12.11.4 OncoTherapy Science Peptide Cancer Vaccine Products Offered
12.11.5 OncoTherapy Science Recent Development
13 Peptide Cancer Vaccine Manufacturing Cost Analysis
13.1 Peptide Cancer Vaccine Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
13.4 Peptide Cancer Vaccine Industrial Chain Analysis
14 麻豆原创ing Channel, Distributors and Customers
14.1 麻豆原创ing Channel
14.2 Peptide Cancer Vaccine Distributors List
14.3 Peptide Cancer Vaccine Customers
15 麻豆原创 Dynamics
15.1 Peptide Cancer Vaccine Industry Trends
15.2 Peptide Cancer Vaccine 麻豆原创 Drivers
15.3 Peptide Cancer Vaccine 麻豆原创 Challenges
15.4 Peptide Cancer Vaccine 麻豆原创 Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

Companies Mentioned:

Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.